{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:29:47Z","timestamp":1790688587303,"version":"4.1.0"},"reference-count":83,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GIRCI M\u00e9diterran\u00e9e","award":["VALO DATA 2021"],"award-info":[{"award-number":["VALO DATA 2021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Liquid biopsy and circulating tumor cell (CTC) screening has gained interest over the last two decades for detecting almost all solid malignancies. To date, the major limitation in terms of the applicability of CTC screening in daily clinical practice is the lack of reproducibility due to the high number of platforms available that use various technologies (e.g., label-dependent versus label-free detection). Only a few studies have compared different CTC platforms. The aim of this study was to compare the efficiency of four commercially available CTC platforms (Vortex (VTX-1), ClearCell FX, ISET, and Cellsearch) for the detection and identification of uveal melanoma cells (OMM 2.3 cell line). Tumor cells were seeded in RPMI medium and venous blood from healthy donors, and then processed similarly using these four platforms. Melan-A immunochemistry was performed to identify tumor cells, except when the Cellsearch device was used (automated identification). The mean overall recovery rates (with mean recovered cells) were 39.2% (19.92), 22.2% (11.31), 8.9% (4.85), and 1.1% (0.20) for the ISET, Vortex (VTX-1), ClearCell FX, and CellSearch platforms, respectively. Although paramount, the recovery rate is not sufficient to assess a CTC platform. Other parameters, such as the purpose for using a platform (diagnosis, genetics, drug sensitivity, or patient-derived xenograft models), reproducibility, purity, user-friendliness, cost-effectiveness, and ergonomics, should also be considered before they can be used in daily clinical practice and are discussed in this article.<\/jats:p>","DOI":"10.3390\/ijms241311075","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:33:42Z","timestamp":1688517222000},"page":"11075","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Assessment of Different Circulating Tumor Cell Platforms for Uveal Melanoma: Potential Impact for Future Routine Clinical Practice"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3836-7126","authenticated-orcid":false,"given":"Arnaud","family":"Martel","sequence":"first","affiliation":[{"name":"Ophthalmology Department, University Hospital of Nice, Cote d\u2019Azur University, 06 000 Nice, France"},{"name":"Institute for Research on Cancer and Aging, Nice (IRCAN), FHU OncoAge, Cote d\u2019Azur University, 06 000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1025-3429","authenticated-orcid":false,"given":"Baharia","family":"Mograbi","sequence":"additional","affiliation":[{"name":"Institute for Research on Cancer and Aging, Nice (IRCAN), FHU OncoAge, Cote d\u2019Azur University, 06 000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnabe","family":"Romeo","sequence":"additional","affiliation":[{"name":"Institute for Research on Cancer and Aging, Nice (IRCAN), FHU OncoAge, Cote d\u2019Azur University, 06 000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauris","family":"Gastaud","sequence":"additional","affiliation":[{"name":"Oncology Department, Antoine Lacassagne Cancer Center, 06 000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome","family":"Lalvee","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical and Experimental Pathology, University Hospital of Nice, FHU OncoAge, Cote d\u2019Azur University, Biobank BB-0033-00025, 06 000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Zahaf","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical and Experimental Pathology, University Hospital of Nice, FHU OncoAge, Cote d\u2019Azur University, Biobank BB-0033-00025, 06 000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Fayada","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical and Experimental Pathology, University Hospital of Nice, FHU OncoAge, Cote d\u2019Azur University, Biobank BB-0033-00025, 06 000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2274-0256","authenticated-orcid":false,"given":"Sacha","family":"Nahon-Esteve","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, University Hospital of Nice, Cote d\u2019Azur University, 06 000 Nice, France"},{"name":"Inserm, Biology and Pathologies of Melanocytes, Team1, Equipe labellis\u00e9e Ligue 2020 and Equipe labellis\u00e9e ARC 2019, Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, 06 100 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Bonnetaud","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical and Experimental Pathology, University Hospital of Nice, FHU OncoAge, Cote d\u2019Azur University, Biobank BB-0033-00025, 06 000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Salah","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical and Experimental Pathology, University Hospital of Nice, FHU OncoAge, Cote d\u2019Azur University, Biobank BB-0033-00025, 06 000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Tanga","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical and Experimental Pathology, University Hospital of Nice, FHU OncoAge, Cote d\u2019Azur University, Biobank BB-0033-00025, 06 000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1700-8570","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Baillif","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, University Hospital of Nice, Cote d\u2019Azur University, 06 000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine","family":"Bertolotto","sequence":"additional","affiliation":[{"name":"Inserm, Biology and Pathologies of Melanocytes, Team1, Equipe labellis\u00e9e Ligue 2020 and Equipe labellis\u00e9e ARC 2019, Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, 06 100 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1692-2440","authenticated-orcid":false,"given":"Sandra","family":"Lassalle","sequence":"additional","affiliation":[{"name":"Institute for Research on Cancer and Aging, Nice (IRCAN), FHU OncoAge, Cote d\u2019Azur University, 06 000 Nice, France"},{"name":"Laboratory of Clinical and Experimental Pathology, University Hospital of Nice, FHU OncoAge, Cote d\u2019Azur University, Biobank BB-0033-00025, 06 000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0431-9353","authenticated-orcid":false,"given":"Paul","family":"Hofman","sequence":"additional","affiliation":[{"name":"Institute for Research on Cancer and Aging, Nice (IRCAN), FHU OncoAge, Cote d\u2019Azur University, 06 000 Nice, France"},{"name":"Laboratory of Clinical and Experimental Pathology, University Hospital of Nice, FHU OncoAge, Cote d\u2019Azur University, Biobank BB-0033-00025, 06 000 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: Trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/eye.2016.275","article-title":"Uveal melanoma: Relatively rare but deadly cancer","volume":"31","author":"Kaliki","year":"2017","journal-title":"Eye"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.ijrobp.2012.10.005","article-title":"Local recurrence after uveal melanoma proton beam therapy: Recurrence types and prognostic consequences","volume":"85","author":"Caujolle","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ajo.2016.02.027","article-title":"Outcomes After Proton Beam Therapy for Large Choroidal Melanomas in 492 Patients","volume":"165","author":"Bensoussan","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Lamas, N.J., Martel, A., Nahon-Est\u00e8ve, S., Goffinet, S., Macocco, A., Bertolotto, C., Lassalle, S., and Hofman, P. (2021). Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions. Cancers, 14.","DOI":"10.3390\/cancers14010096"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/ICU.0000000000000905","article-title":"Treatment of metastatic uveal melanoma in 2022: Improved treatment regimens and improved prognosis","volume":"33","author":"Reichstein","year":"2022","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1101\/gad.296962.117","article-title":"Focus on cutaneous and uveal melanoma specificities","volume":"31","author":"Pandiani","year":"2017","journal-title":"Genes Dev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3389\/fphar.2020.01123","article-title":"Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015-2018 Years","volume":"11","author":"Mela","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: Treatment options and future prospects","volume":"101","author":"Carvajal","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Seitz, T., John, N., Sommer, J., Dietrich, P., Thasler, W.E., Hartmann, A., Evert, K., Lang, S.A., Bosserhoff, A., and Hellerbrand, C. (2022). Role of Fibroblast Growth Factors in the Crosstalk of Hepatic Stellate Cells and Uveal Melanoma Cells in the Liver Metastatic Niche. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911524"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1167\/iovs.08-2296","article-title":"Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases","volume":"50","author":"Trolet","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","article-title":"Collaborative Ocular Oncology Group report number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma","volume":"119","author":"Onken","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Frizziero, L., Midena, E., Trainiti, S., Londei, D., Bonaldi, L., Bini, S., and Parrozzani, R. (2019). Uveal Melanoma Biopsy: A Review. Cancers, 11.","DOI":"10.3390\/cancers11081075"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000499337","article-title":"Liquid Biopsy: General Concepts","volume":"63","author":"Poulet","year":"2019","journal-title":"Acta Cytol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Im, D.H., Peng, C.-C., Xu, L., Kim, M.E., Ostrow, D., Yellapantula, V., Bootwalla, M., Biegel, J.A., Gai, X., and Prabakar, R.K. (2022). Potential of Aqueous Humor as a Liquid Biopsy for Uveal Melanoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116226"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Martel, A., Baillif, S., Nahon-Esteve, S., Gastaud, L., Bertolotto, C., Rom\u00e9o, B., Mograbi, B., Lassalle, S., and Hofman, P. (2020). Liquid Biopsy for Solid Ophthalmic Malignancies: An Updated Review and Perspectives. Cancers, 12.","DOI":"10.3390\/cancers12113284"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000508613","article-title":"Liquid Biopsy in Uveal Melanoma: Are We There Yet?","volume":"7","author":"Jin","year":"2021","journal-title":"Ocul. Oncol. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"De Bruyn, D.P., Beasley, A.B., Verdijk, R.M., van Poppelen, N.M., Paridaens, D., de Keizer, R.O.B., Naus, N.C., Gray, E.S., de Klein, A., and Brosens, E. (2022). Is Tissue Still the Issue? The Promise of Liquid Biopsy in Uveal Melanoma. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020506"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cncy.22367","article-title":"Liquid biopsy for lung cancer screening: Usefulness of circulating tumor cells and other circulating blood biomarkers","volume":"129","author":"Hofman","year":"2021","journal-title":"Cancer Cytopathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/s41416-022-01723-8","article-title":"Future perspectives of uveal melanoma blood based biomarkers","volume":"126","author":"Beasley","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","article-title":"Circulating tumor cells: Biology and clinical significance","volume":"6","author":"Lin","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_23","first-page":"107","article-title":"Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?","volume":"2","author":"Ilie","year":"2014","journal-title":"Ann. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.molonc.2016.01.007","article-title":"Circulating tumor cell technologies","volume":"10","author":"Ferreira","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Di Capua, D., Bracken-Clarke, D., Ronan, K., Baird, A.-M., and Finn, S. (2021). The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments. Cancers, 13.","DOI":"10.3390\/cancers13163923"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Tamminga, M., Andree, K.C., Hiltermann, T.J.N., Jayat, M., Schuuring, E., van den Bos, H., Spierings, D.C.J., Lansdorp, P.M., Timens, W., and Terstappen, L.W.M.M. (2020). Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch\u00ae and ISET. Cancers, 12.","DOI":"10.3390\/cancers12040896"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10565-018-09454-4","article-title":"Characterization of circulating tumor cells in breast cancer patients by spiral microfluidics","volume":"35","author":"Yin","year":"2019","journal-title":"Cell Biol. Toxicol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s11255-018-1954-2","article-title":"Comparison of two detection systems for circulating tumor cells among patients with renal cell carcinoma","volume":"50","author":"Bai","year":"2018","journal-title":"Int. Urol. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000452556","article-title":"Evaluation of Isolation Methods for Circulating Tumor Cells (CTCs)","volume":"40","author":"Kallergi","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00280-014-2508-7","article-title":"Circulating biomarkers in hepatocellular carcinoma","volume":"74","author":"Morris","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_31","first-page":"306","article-title":"Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches","volume":"7","author":"Krebs","year":"2012","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/bjc.2011.545","article-title":"A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker","volume":"106","author":"Khoja","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/ijc.25819","article-title":"Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: Comparison of the efficacy of the CellSearch AssayTM and the isolation by size of epithelial tumor cell method","volume":"129","author":"Hofman","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1073\/pnas.95.8.4589","article-title":"Detection and characterization of carcinoma cells in the blood","volume":"95","author":"Racila","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41418-020-00730-7","article-title":"Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic disease","volume":"28","author":"Pandiani","year":"2021","journal-title":"Cell Death Differ."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100968","DOI":"10.1016\/j.preteyeres.2021.100968","article-title":"Translation of single-cell transcriptomic analysis of uveal melanomas to clinical oncology","volume":"85","author":"Strub","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"12748","DOI":"10.18632\/oncotarget.7220","article-title":"Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology","volume":"7","author":"Che","year":"2016","journal-title":"Oncotarget"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e1565","DOI":"10.1097\/MD.0000000000001565","article-title":"Circulating Tumor Cell Analyses in Patients with Esophageal Squamous Cell Carcinoma Using Epithelial Marker-Dependent and -Independent Approaches","volume":"94","author":"Li","year":"2015","journal-title":"Medicine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/cancers6010323","article-title":"Circulating tumor cells detection and counting in uveal melanomas by a filtration-based method","volume":"6","author":"Mazzini","year":"2014","journal-title":"Cancers"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/CMR.0b013e32833906e3","article-title":"Tyrosinase mRNA levels in the blood of uveal melanoma patients: Correlation with the number of circulating tumor cells and tumor progression","volume":"20","author":"Pinzani","year":"2010","journal-title":"Melanoma Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1002\/cam4.1832","article-title":"The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer","volume":"7","author":"Kulasinghe","year":"2018","journal-title":"Cancer Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Yap, Y.-S., Leong, M.C., Chua, Y.W., Loh, K.W.J., Lee, G.E., Lim, E.H., Dent, R., Ng, R.C.H., Lim, J.H.-C., and Singh, G. (2019). Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0221305"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"480","DOI":"10.21037\/atm.2016.12.28","article-title":"Inertia based microfluidic capture and characterisation of circulating tumour cells for the diagnosis of lung cancer","volume":"4","author":"Chudasama","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"064116","DOI":"10.1063\/1.4937895","article-title":"High efficiency vortex trapping of circulating tumor cells","volume":"9","author":"Dhar","year":"2015","journal-title":"Biomicrofluidics"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1039\/C3LC50689D","article-title":"Size-selective collection of circulating tumor cells using Vortex technology","volume":"14","author":"Sollier","year":"2014","journal-title":"Lab. Chip"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41698-017-0015-0","article-title":"Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology","volume":"1","author":"Renier","year":"2017","journal-title":"NPJ Precis. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/14737159.2016.1255144","article-title":"Improving the CellSearch\u00ae system","volume":"16","author":"Swennenhuis","year":"2016","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/ijc.28436","article-title":"Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma","volume":"134","author":"Bidard","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Anand, K., Roszik, J., Gombos, D., Upshaw, J., Sarli, V., Meas, S., Lucci, A., Hall, C., and Patel, S. (2019). Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma. Cancers, 11.","DOI":"10.3390\/cancers11060856"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.ebiom.2015.09.019","article-title":"Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells","volume":"2","author":"Terai","year":"2015","journal-title":"EBioMedicine"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Bande, M.F., Santiago, M., Muinelo-Romay, L., Blanco, M.J., Mera, P., Capeans, C., Pardo, M., and Pi\u00f1eiro, A. (2015). Detection of circulating melanoma cells in choroidal melanocytic lesions. BMC Res. Notes, 8.","DOI":"10.1186\/s13104-015-1420-5"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3109\/02713680903262205","article-title":"Possible implications of MCAM expression in metastasis and non-metastatic of primary uveal melanoma patients","volume":"34","author":"Beutel","year":"2009","journal-title":"Curr. Eye Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00428-007-0498-0","article-title":"Expression and distribution of MUC18 in human uveal melanoma","volume":"451","author":"Lai","year":"2007","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Beasley, A.B., Isaacs, T.W., Vermeulen, T., Freeman, J., DeSousa, J.-L., Bhikoo, R., Hennessy, D., Reid, A., Chen, F.K., and Bentel, J. (2021). Analysis of Circulating Tumour Cells in Early-Stage Uveal Melanoma: Evaluation of Tumour Marker Expression to Increase Capture. Cancers, 13.","DOI":"10.3390\/cancers13235990"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1038\/s41598-023-33179-y","article-title":"Measuring antigen expression of cancer cell lines and circulating tumour cells","volume":"13","author":"Mentink","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1167\/iovs.14-14512","article-title":"Identification of circulating melanoma cells in uveal melanoma patients by dual-marker immunoenrichment","volume":"55","author":"Tura","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1158\/1078-0432.CCR-08-0012","article-title":"Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma","volume":"14","author":"Ulmer","year":"2008","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1755-3768.2009.01617.x","article-title":"Circulating melanoma cells in peripheral blood of patients with uveal melanoma before and after different therapies and association with prognostic parameters: A pilot study","volume":"89","author":"Suesskind","year":"2011","journal-title":"Acta Ophthalmol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/j.1755-3768.2008.01378.x","article-title":"Immunomagnetic detection of micrometastatic cells in bone marrow in uveal melanoma patients","volume":"87","author":"Eide","year":"2009","journal-title":"Acta Ophthalmol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Laget, S., Broncy, L., Hormigos, K., Dhingra, D.M., BenMohamed, F., Capiod, T., Osteras, M., Farinelli, L., Jackson, S., and Paterlini-Br\u00e9chot, P. (2017). Technical Insights into Highly Sensitive Isolation and Molecular Characterization of Fixed and Live Circulating Tumor Cells for Early Detection of Tumor Invasion. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0169427"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41598-018-19245-w","article-title":"Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer","volume":"8","author":"Dhar","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"14622","DOI":"10.1038\/ncomms14622","article-title":"Profiling protein expression in circulating tumour cells using microfluidic western blotting","volume":"8","author":"Sinkala","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41525-017-0034-3","article-title":"Workflow optimization of whole genome amplification and targeted panel sequencing for CTC mutation detection","volume":"2","author":"Liu","year":"2017","journal-title":"NPJ Genom. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"85349","DOI":"10.18632\/oncotarget.13350","article-title":"Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Takahashi, Y., Shirai, K., Ijiri, Y., Morita, E., Yoshida, T., Iwanaga, S., and Yanagida, M. (2020). Integrated system for detection and molecular characterization of circulating tumor cells. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0237506"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/annonc\/mdw122","article-title":"Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: A clinical case study","volume":"27","author":"Morrow","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0002-9440(10)64706-2","article-title":"Isolation by size of epithelial tumor cells: A new method for the immunomorphological and molecular characterization of circulatingtumor cells","volume":"156","author":"Vona","year":"2000","journal-title":"Am. J. Pathol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"295","DOI":"10.7785\/tcrt.2012.500328","article-title":"Recent advances and prospects in the isolation by size of epithelial tumor cells (ISET) methodology","volume":"12","author":"Ma","year":"2013","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/15384047.2015.1070991","article-title":"Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer","volume":"16","author":"Buim","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Cummings, J., Morris, K., Zhou, C., Sloane, R., Lancashire, M., Morris, D., Bramley, S., Krebs, M., Khoja, L., and Dive, C. (2013). Method validation of circulating tumour cell enumeration at low cell counts. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-415"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10585-020-10033-3","article-title":"Tumor shedding and metastatic progression after tumor excision in patient-derived orthotopic xenograft models of triple-negative breast cancer","volume":"37","author":"Razmara","year":"2020","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"683318","DOI":"10.3389\/fonc.2021.683318","article-title":"Survival, Chemotherapy and Chemosensitivity Predicted by CTC Cultured In Vitro of SCLC Patients","volume":"11","author":"Ju","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_74","first-page":"90","article-title":"New benchmarks and design criteria for laboratory consolidations","volume":"17","author":"Wilson","year":"2003","journal-title":"Clin. Leadersh. Manag. Rev. J. CLMA"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Martel, A., Gastaud, L., Bonnetaud, C., Nahon-Esteve, S., Washetine, K., Bordone, O., Salah, M., Tanga, V., Fayada, J., and Lespinet, V. (2023). Need for a Dedicated Ophthalmic Malignancy Clinico-Biological Biobank: The Nice Ocular MAlignancy (NOMA) Biobank. Cancers, 15.","DOI":"10.3390\/cancers15082372"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/14737167.2023.2140139","article-title":"The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology","volume":"23","author":"Mela","year":"2023","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrc3820","article-title":"Challenges in circulating tumour cell research","volume":"14","author":"Pantel","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/eye.2012.255","article-title":"Molecular pathology of uveal melanoma","volume":"27","author":"Coupland","year":"2013","journal-title":"Eye"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.exer.2012.04.010","article-title":"Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival","volume":"100","author":"Cebulla","year":"2012","journal-title":"Exp. Eye Res."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Heeke, S., Mograbi, B., Alix-Panabi\u00e8res, C., and Hofman, P. (2019). Never Travel Alone: The Crosstalk of Circulating Tumor Cells and the Blood Microenvironment. Cells, 8.","DOI":"10.3390\/cells8070714"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/cncr.29727","article-title":"Uveal melanoma: From diagnosis to treatment and the science in between","volume":"122","author":"Chattopadhyay","year":"2016","journal-title":"Cancer"},{"key":"ref_82","first-page":"T5","article-title":"Uveal Melanoma Cell Lines: Where do they come from? (An American Ophthalmological Society Thesis)","volume":"114","author":"Jager","year":"2016","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1755-148X.2012.00971.x","article-title":"Genetic and molecular characterization of uveal melanoma cell lines","volume":"25","author":"Griewank","year":"2012","journal-title":"Pigment. Cell Melanoma Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/11075\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:05:58Z","timestamp":1760126758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/11075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":83,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241311075"],"URL":"https:\/\/doi.org\/10.3390\/ijms241311075","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]}}}